1. Home
  2. RFI vs ALT Comparison

RFI vs ALT Comparison

Compare RFI & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFI
  • ALT
  • Stock Information
  • Founded
  • RFI 1992
  • ALT 1997
  • Country
  • RFI United States
  • ALT United States
  • Employees
  • RFI N/A
  • ALT N/A
  • Industry
  • RFI Investment Managers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RFI Finance
  • ALT Health Care
  • Exchange
  • RFI Nasdaq
  • ALT Nasdaq
  • Market Cap
  • RFI 313.7M
  • ALT 348.6M
  • IPO Year
  • RFI N/A
  • ALT N/A
  • Fundamental
  • Price
  • RFI $11.42
  • ALT $4.05
  • Analyst Decision
  • RFI
  • ALT Strong Buy
  • Analyst Count
  • RFI 0
  • ALT 7
  • Target Price
  • RFI N/A
  • ALT $16.50
  • AVG Volume (30 Days)
  • RFI 69.8K
  • ALT 2.7M
  • Earning Date
  • RFI 01-01-0001
  • ALT 11-07-2025
  • Dividend Yield
  • RFI 8.25%
  • ALT N/A
  • EPS Growth
  • RFI N/A
  • ALT N/A
  • EPS
  • RFI N/A
  • ALT N/A
  • Revenue
  • RFI N/A
  • ALT $20,000.00
  • Revenue This Year
  • RFI N/A
  • ALT N/A
  • Revenue Next Year
  • RFI N/A
  • ALT N/A
  • P/E Ratio
  • RFI N/A
  • ALT N/A
  • Revenue Growth
  • RFI N/A
  • ALT N/A
  • 52 Week Low
  • RFI $9.62
  • ALT $2.90
  • 52 Week High
  • RFI $12.52
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • RFI 25.82
  • ALT 54.78
  • Support Level
  • RFI $11.82
  • ALT $3.93
  • Resistance Level
  • RFI $11.93
  • ALT $4.15
  • Average True Range (ATR)
  • RFI 0.14
  • ALT 0.16
  • MACD
  • RFI -0.04
  • ALT 0.00
  • Stochastic Oscillator
  • RFI 7.70
  • ALT 72.60

About RFI Cohen & Steers Total Return Realty Fund Inc.

Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: